Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review
Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID-19). A thorough understanding of the current body of evidence regarding benefits and risks of the...
Uloženo v:
| Vydáno v: | Cochrane database of systematic reviews Ročník 5; s. CD013600 |
|---|---|
| Hlavní autoři: | , , , , , , , , , , , , , |
| Médium: | Journal Article |
| Jazyk: | angličtina |
| Vydáno: |
England
20.05.2021
|
| Témata: | |
| ISSN: | 1469-493X, 1469-493X |
| On-line přístup: | Zjistit podrobnosti o přístupu |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!
|
| Abstract | Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID-19). A thorough understanding of the current body of evidence regarding benefits and risks of these interventions is required. OBJECTIVES: Using a living systematic review approach, to assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence.
To identify completed and ongoing studies, we searched the World Health Organization (WHO) COVID-19 Global literature on coronavirus disease Research Database, MEDLINE, Embase, the Cochrane COVID-19 Study Register, the Epistemonikos COVID-19 L*OVE Platform, and trial registries. Searches were done on 17 March 2021.
We included randomised controlled trials (RCTs) evaluating convalescent plasma or hyperimmune immunoglobulin for COVID-19, irrespective of disease severity, age, gender or ethnicity. For safety assessments, we also included non-controlled non-randomised studies of interventions (NRSIs) if 500 or more participants were included. We excluded studies that included populations with other coronavirus diseases (severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS)), as well as studies evaluating standard immunoglobulin.
We followed standard Cochrane methodology. To assess bias in included studies, we used the Cochrane 'Risk of Bias 2' tool for RCTs, and for NRSIs, the assessment criteria for observational studies, provided by Cochrane Childhood Cancer. We rated the certainty of evidence, using the GRADE approach, for the following outcomes: all-cause mortality, improvement and worsening of clinical status (for individuals with moderate to severe disease), development of severe clinical COVID-19 symptoms (for individuals with asymptomatic or mild disease), quality of life (including fatigue and functional independence), grade 3 or 4 adverse events, and serious adverse events.
We included 13 studies (12 RCTs, 1 NRSI) with 48,509 participants, of whom 41,880 received convalescent plasma. We did not identify any completed studies evaluating hyperimmune immunoglobulin. We identified a further 100 ongoing studies evaluating convalescent plasma or hyperimmune immunoglobulin, and 33 studies reporting as being completed or terminated. Individuals with a confirmed diagnosis of COVID-19 and moderate to severe disease Eleven RCTs and one NRSI investigated the use of convalescent plasma for 48,349 participants with moderate to severe disease. Nine RCTs compared convalescent plasma to placebo treatment or standard care alone, and two compared convalescent plasma to standard plasma (results not included in abstract). Effectiveness of convalescent plasma We included data on nine RCTs (12,875 participants) to assess the effectiveness of convalescent plasma compared to placebo or standard care alone. Convalescent plasma does not reduce all-cause mortality at up to day 28 (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.92 to 1.05; 7 RCTs, 12,646 participants; high-certainty evidence). It has little to no impact on clinical improvement for all participants when assessed by liberation from respiratory support (RR not estimable; 8 RCTs, 12,682 participants; high-certainty evidence). It has little to no impact on the chance of being weaned or liberated from invasive mechanical ventilation for the subgroup of participants requiring invasive mechanical ventilation at baseline (RR 1.04, 95% CI 0.57 to 1.93; 2 RCTs, 630 participants; low-certainty evidence). It does not reduce the need for invasive mechanical ventilation (RR 0.98, 95% CI 0.89 to 1.08; 4 RCTs, 11,765 participants; high-certainty evidence). We did not identify any subgroup differences. We did not identify any studies reporting quality of life, and therefore, do not know whether convalescent plasma has any impact on quality of life. One RCT assessed resolution of fatigue on day 7, but we are very uncertain about the effect (RR 1.21, 95% CI 1.02 to 1.42; 309 participants; very low-certainty evidence). Safety of convalescent plasma We included results from eight RCTs, and one NRSI, to assess the safety of convalescent plasma. Some of the RCTs reported on safety data only for the convalescent plasma group. We are uncertain whether convalescent plasma increases or reduces the risk of grade 3 and 4 adverse events (RR 0.90, 95% CI 0.58 to 1.41; 4 RCTs, 905 participants; low-certainty evidence), and serious adverse events (RR 1.24, 95% CI 0.81 to 1.90; 2 RCTs, 414 participants; low-certainty evidence). A summary of reported events of the NRSI (reporting safety data for 20,000 of 35,322 transfused participants), and four RCTs reporting safety data only for transfused participants (6125 participants) are included in the full text. Individuals with a confirmed diagnosis of SARS-CoV-2 infection and asymptomatic or mild disease We identified one RCT reporting on 160 participants, comparing convalescent plasma to placebo treatment (saline). Effectiveness of convalescent plasma We are very uncertain about the effect of convalescent plasma on all-cause mortality (RR 0.50, 95% CI 0.09 to 2.65; very low-certainty evidence). We are uncertain about the effect of convalescent plasma on developing severe clinical COVID-19 symptoms (RR not estimable; low-certainty evidence). We identified no study reporting quality of life. Safety of convalescent plasma We do not know whether convalescent plasma is associated with a higher risk of grade 3 or 4 adverse events (very low-certainty evidence), or serious adverse events (very low-certainty evidence). This is a living systematic review. We search weekly for new evidence and update the review when we identify relevant new evidence. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
We have high certainty in the evidence that convalescent plasma for the treatment of individuals with moderate to severe disease does not reduce mortality and has little to no impact on measures of clinical improvement. We are uncertain about the adverse effects of convalescent plasma. While major efforts to conduct research on COVID-19 are being made, heterogeneous reporting of outcomes is still problematic. There are 100 ongoing studies and 33 studies reporting in a study registry as being completed or terminated. Publication of ongoing studies might resolve some of the uncertainties around hyperimmune immunoglobulin therapy for people with any disease severity, and convalescent plasma therapy for people with asymptomatic or mild disease. |
|---|---|
| AbstractList | Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID-19). A thorough understanding of the current body of evidence regarding benefits and risks of these interventions is required. OBJECTIVES: Using a living systematic review approach, to assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence.
To identify completed and ongoing studies, we searched the World Health Organization (WHO) COVID-19 Global literature on coronavirus disease Research Database, MEDLINE, Embase, the Cochrane COVID-19 Study Register, the Epistemonikos COVID-19 L*OVE Platform, and trial registries. Searches were done on 17 March 2021.
We included randomised controlled trials (RCTs) evaluating convalescent plasma or hyperimmune immunoglobulin for COVID-19, irrespective of disease severity, age, gender or ethnicity. For safety assessments, we also included non-controlled non-randomised studies of interventions (NRSIs) if 500 or more participants were included. We excluded studies that included populations with other coronavirus diseases (severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS)), as well as studies evaluating standard immunoglobulin.
We followed standard Cochrane methodology. To assess bias in included studies, we used the Cochrane 'Risk of Bias 2' tool for RCTs, and for NRSIs, the assessment criteria for observational studies, provided by Cochrane Childhood Cancer. We rated the certainty of evidence, using the GRADE approach, for the following outcomes: all-cause mortality, improvement and worsening of clinical status (for individuals with moderate to severe disease), development of severe clinical COVID-19 symptoms (for individuals with asymptomatic or mild disease), quality of life (including fatigue and functional independence), grade 3 or 4 adverse events, and serious adverse events.
We included 13 studies (12 RCTs, 1 NRSI) with 48,509 participants, of whom 41,880 received convalescent plasma. We did not identify any completed studies evaluating hyperimmune immunoglobulin. We identified a further 100 ongoing studies evaluating convalescent plasma or hyperimmune immunoglobulin, and 33 studies reporting as being completed or terminated. Individuals with a confirmed diagnosis of COVID-19 and moderate to severe disease Eleven RCTs and one NRSI investigated the use of convalescent plasma for 48,349 participants with moderate to severe disease. Nine RCTs compared convalescent plasma to placebo treatment or standard care alone, and two compared convalescent plasma to standard plasma (results not included in abstract). Effectiveness of convalescent plasma We included data on nine RCTs (12,875 participants) to assess the effectiveness of convalescent plasma compared to placebo or standard care alone. Convalescent plasma does not reduce all-cause mortality at up to day 28 (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.92 to 1.05; 7 RCTs, 12,646 participants; high-certainty evidence). It has little to no impact on clinical improvement for all participants when assessed by liberation from respiratory support (RR not estimable; 8 RCTs, 12,682 participants; high-certainty evidence). It has little to no impact on the chance of being weaned or liberated from invasive mechanical ventilation for the subgroup of participants requiring invasive mechanical ventilation at baseline (RR 1.04, 95% CI 0.57 to 1.93; 2 RCTs, 630 participants; low-certainty evidence). It does not reduce the need for invasive mechanical ventilation (RR 0.98, 95% CI 0.89 to 1.08; 4 RCTs, 11,765 participants; high-certainty evidence). We did not identify any subgroup differences. We did not identify any studies reporting quality of life, and therefore, do not know whether convalescent plasma has any impact on quality of life. One RCT assessed resolution of fatigue on day 7, but we are very uncertain about the effect (RR 1.21, 95% CI 1.02 to 1.42; 309 participants; very low-certainty evidence). Safety of convalescent plasma We included results from eight RCTs, and one NRSI, to assess the safety of convalescent plasma. Some of the RCTs reported on safety data only for the convalescent plasma group. We are uncertain whether convalescent plasma increases or reduces the risk of grade 3 and 4 adverse events (RR 0.90, 95% CI 0.58 to 1.41; 4 RCTs, 905 participants; low-certainty evidence), and serious adverse events (RR 1.24, 95% CI 0.81 to 1.90; 2 RCTs, 414 participants; low-certainty evidence). A summary of reported events of the NRSI (reporting safety data for 20,000 of 35,322 transfused participants), and four RCTs reporting safety data only for transfused participants (6125 participants) are included in the full text. Individuals with a confirmed diagnosis of SARS-CoV-2 infection and asymptomatic or mild disease We identified one RCT reporting on 160 participants, comparing convalescent plasma to placebo treatment (saline). Effectiveness of convalescent plasma We are very uncertain about the effect of convalescent plasma on all-cause mortality (RR 0.50, 95% CI 0.09 to 2.65; very low-certainty evidence). We are uncertain about the effect of convalescent plasma on developing severe clinical COVID-19 symptoms (RR not estimable; low-certainty evidence). We identified no study reporting quality of life. Safety of convalescent plasma We do not know whether convalescent plasma is associated with a higher risk of grade 3 or 4 adverse events (very low-certainty evidence), or serious adverse events (very low-certainty evidence). This is a living systematic review. We search weekly for new evidence and update the review when we identify relevant new evidence. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.
We have high certainty in the evidence that convalescent plasma for the treatment of individuals with moderate to severe disease does not reduce mortality and has little to no impact on measures of clinical improvement. We are uncertain about the adverse effects of convalescent plasma. While major efforts to conduct research on COVID-19 are being made, heterogeneous reporting of outcomes is still problematic. There are 100 ongoing studies and 33 studies reporting in a study registry as being completed or terminated. Publication of ongoing studies might resolve some of the uncertainties around hyperimmune immunoglobulin therapy for people with any disease severity, and convalescent plasma therapy for people with asymptomatic or mild disease. Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID-19). A thorough understanding of the current body of evidence regarding benefits and risks of these interventions is required. OBJECTIVES: Using a living systematic review approach, to assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence.BACKGROUNDConvalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential therapies for coronavirus disease 2019 (COVID-19). A thorough understanding of the current body of evidence regarding benefits and risks of these interventions is required. OBJECTIVES: Using a living systematic review approach, to assess whether convalescent plasma or hyperimmune immunoglobulin transfusion is effective and safe in the treatment of people with COVID-19; and to maintain the currency of the evidence.To identify completed and ongoing studies, we searched the World Health Organization (WHO) COVID-19 Global literature on coronavirus disease Research Database, MEDLINE, Embase, the Cochrane COVID-19 Study Register, the Epistemonikos COVID-19 L*OVE Platform, and trial registries. Searches were done on 17 March 2021.SEARCH METHODSTo identify completed and ongoing studies, we searched the World Health Organization (WHO) COVID-19 Global literature on coronavirus disease Research Database, MEDLINE, Embase, the Cochrane COVID-19 Study Register, the Epistemonikos COVID-19 L*OVE Platform, and trial registries. Searches were done on 17 March 2021.We included randomised controlled trials (RCTs) evaluating convalescent plasma or hyperimmune immunoglobulin for COVID-19, irrespective of disease severity, age, gender or ethnicity. For safety assessments, we also included non-controlled non-randomised studies of interventions (NRSIs) if 500 or more participants were included. We excluded studies that included populations with other coronavirus diseases (severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS)), as well as studies evaluating standard immunoglobulin.SELECTION CRITERIAWe included randomised controlled trials (RCTs) evaluating convalescent plasma or hyperimmune immunoglobulin for COVID-19, irrespective of disease severity, age, gender or ethnicity. For safety assessments, we also included non-controlled non-randomised studies of interventions (NRSIs) if 500 or more participants were included. We excluded studies that included populations with other coronavirus diseases (severe acute respiratory syndrome (SARS) or Middle East respiratory syndrome (MERS)), as well as studies evaluating standard immunoglobulin.We followed standard Cochrane methodology. To assess bias in included studies, we used the Cochrane 'Risk of Bias 2' tool for RCTs, and for NRSIs, the assessment criteria for observational studies, provided by Cochrane Childhood Cancer. We rated the certainty of evidence, using the GRADE approach, for the following outcomes: all-cause mortality, improvement and worsening of clinical status (for individuals with moderate to severe disease), development of severe clinical COVID-19 symptoms (for individuals with asymptomatic or mild disease), quality of life (including fatigue and functional independence), grade 3 or 4 adverse events, and serious adverse events.DATA COLLECTION AND ANALYSISWe followed standard Cochrane methodology. To assess bias in included studies, we used the Cochrane 'Risk of Bias 2' tool for RCTs, and for NRSIs, the assessment criteria for observational studies, provided by Cochrane Childhood Cancer. We rated the certainty of evidence, using the GRADE approach, for the following outcomes: all-cause mortality, improvement and worsening of clinical status (for individuals with moderate to severe disease), development of severe clinical COVID-19 symptoms (for individuals with asymptomatic or mild disease), quality of life (including fatigue and functional independence), grade 3 or 4 adverse events, and serious adverse events.We included 13 studies (12 RCTs, 1 NRSI) with 48,509 participants, of whom 41,880 received convalescent plasma. We did not identify any completed studies evaluating hyperimmune immunoglobulin. We identified a further 100 ongoing studies evaluating convalescent plasma or hyperimmune immunoglobulin, and 33 studies reporting as being completed or terminated. Individuals with a confirmed diagnosis of COVID-19 and moderate to severe disease Eleven RCTs and one NRSI investigated the use of convalescent plasma for 48,349 participants with moderate to severe disease. Nine RCTs compared convalescent plasma to placebo treatment or standard care alone, and two compared convalescent plasma to standard plasma (results not included in abstract). Effectiveness of convalescent plasma We included data on nine RCTs (12,875 participants) to assess the effectiveness of convalescent plasma compared to placebo or standard care alone. Convalescent plasma does not reduce all-cause mortality at up to day 28 (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.92 to 1.05; 7 RCTs, 12,646 participants; high-certainty evidence). It has little to no impact on clinical improvement for all participants when assessed by liberation from respiratory support (RR not estimable; 8 RCTs, 12,682 participants; high-certainty evidence). It has little to no impact on the chance of being weaned or liberated from invasive mechanical ventilation for the subgroup of participants requiring invasive mechanical ventilation at baseline (RR 1.04, 95% CI 0.57 to 1.93; 2 RCTs, 630 participants; low-certainty evidence). It does not reduce the need for invasive mechanical ventilation (RR 0.98, 95% CI 0.89 to 1.08; 4 RCTs, 11,765 participants; high-certainty evidence). We did not identify any subgroup differences. We did not identify any studies reporting quality of life, and therefore, do not know whether convalescent plasma has any impact on quality of life. One RCT assessed resolution of fatigue on day 7, but we are very uncertain about the effect (RR 1.21, 95% CI 1.02 to 1.42; 309 participants; very low-certainty evidence). Safety of convalescent plasma We included results from eight RCTs, and one NRSI, to assess the safety of convalescent plasma. Some of the RCTs reported on safety data only for the convalescent plasma group. We are uncertain whether convalescent plasma increases or reduces the risk of grade 3 and 4 adverse events (RR 0.90, 95% CI 0.58 to 1.41; 4 RCTs, 905 participants; low-certainty evidence), and serious adverse events (RR 1.24, 95% CI 0.81 to 1.90; 2 RCTs, 414 participants; low-certainty evidence). A summary of reported events of the NRSI (reporting safety data for 20,000 of 35,322 transfused participants), and four RCTs reporting safety data only for transfused participants (6125 participants) are included in the full text. Individuals with a confirmed diagnosis of SARS-CoV-2 infection and asymptomatic or mild disease We identified one RCT reporting on 160 participants, comparing convalescent plasma to placebo treatment (saline). Effectiveness of convalescent plasma We are very uncertain about the effect of convalescent plasma on all-cause mortality (RR 0.50, 95% CI 0.09 to 2.65; very low-certainty evidence). We are uncertain about the effect of convalescent plasma on developing severe clinical COVID-19 symptoms (RR not estimable; low-certainty evidence). We identified no study reporting quality of life. Safety of convalescent plasma We do not know whether convalescent plasma is associated with a higher risk of grade 3 or 4 adverse events (very low-certainty evidence), or serious adverse events (very low-certainty evidence). This is a living systematic review. We search weekly for new evidence and update the review when we identify relevant new evidence. Please refer to the Cochrane Database of Systematic Reviews for the current status of this review.MAIN RESULTSWe included 13 studies (12 RCTs, 1 NRSI) with 48,509 participants, of whom 41,880 received convalescent plasma. We did not identify any completed studies evaluating hyperimmune immunoglobulin. We identified a further 100 ongoing studies evaluating convalescent plasma or hyperimmune immunoglobulin, and 33 studies reporting as being completed or terminated. Individuals with a confirmed diagnosis of COVID-19 and moderate to severe disease Eleven RCTs and one NRSI investigated the use of convalescent plasma for 48,349 participants with moderate to severe disease. Nine RCTs compared convalescent plasma to placebo treatment or standard care alone, and two compared convalescent plasma to standard plasma (results not included in abstract). Effectiveness of convalescent plasma We included data on nine RCTs (12,875 participants) to assess the effectiveness of convalescent plasma compared to placebo or standard care alone. Convalescent plasma does not reduce all-cause mortality at up to day 28 (risk ratio (RR) 0.98, 95% confidence interval (CI) 0.92 to 1.05; 7 RCTs, 12,646 participants; high-certainty evidence). It has little to no impact on clinical improvement for all participants when assessed by liberation from respiratory support (RR not estimable; 8 RCTs, 12,682 participants; high-certainty evidence). It has little to no impact on the chance of being weaned or liberated from invasive mechanical ventilation for the subgroup of participants requiring invasive mechanical ventilation at baseline (RR 1.04, 95% CI 0.57 to 1.93; 2 RCTs, 630 participants; low-certainty evidence). It does not reduce the need for invasive mechanical ventilation (RR 0.98, 95% CI 0.89 to 1.08; 4 RCTs, 11,765 participants; high-certainty evidence). We did not identify any subgroup differences. We did not identify any |
| Author | Lamikanra, Abigail A Piechotta, Vanessa Estcourt, Lise J Dorando, Elena Roberts, David J Kimber, Catherine Chai, Khai Li Monsef, Ina Skoetz, Nicole McQuilten, Zoe So-Osman, Cynthia Wood, Erica M Valk, Sarah J Iannizzi, Claire |
| Author_xml | – sequence: 1 givenname: Vanessa surname: Piechotta fullname: Piechotta, Vanessa organization: Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany – sequence: 2 givenname: Claire surname: Iannizzi fullname: Iannizzi, Claire organization: Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany – sequence: 3 givenname: Khai Li surname: Chai fullname: Chai, Khai Li organization: Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia – sequence: 4 givenname: Sarah J surname: Valk fullname: Valk, Sarah J organization: Department of Clinical Epidemiology, Leiden University Medical Center, Leiden, Netherlands – sequence: 5 givenname: Catherine surname: Kimber fullname: Kimber, Catherine organization: Systematic Review Initiative, NHS Blood and Transplant, Oxford, UK – sequence: 6 givenname: Elena surname: Dorando fullname: Dorando, Elena organization: Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany – sequence: 7 givenname: Ina surname: Monsef fullname: Monsef, Ina organization: Cochrane Haematology, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany – sequence: 8 givenname: Erica M surname: Wood fullname: Wood, Erica M organization: Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia – sequence: 9 givenname: Abigail A surname: Lamikanra fullname: Lamikanra, Abigail A organization: Clinical, Research and Development, NHS Blood and Transplant, Oxford, UK – sequence: 10 givenname: David J surname: Roberts fullname: Roberts, David J organization: Systematic Review Initiative, NHS Blood and Transplant, Oxford, UK – sequence: 11 givenname: Zoe surname: McQuilten fullname: McQuilten, Zoe organization: Transfusion Research Unit, School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia – sequence: 12 givenname: Cynthia surname: So-Osman fullname: So-Osman, Cynthia organization: Erasmus Medical Centre, Rotterdam, Netherlands – sequence: 13 givenname: Lise J surname: Estcourt fullname: Estcourt, Lise J organization: Haematology/Transfusion Medicine, NHS Blood and Transplant, Oxford, UK – sequence: 14 givenname: Nicole surname: Skoetz fullname: Skoetz, Nicole organization: Cochrane Cancer, Department I of Internal Medicine, Center for Integrated Oncology Aachen Bonn Cologne Duesseldorf, Faculty of Medicine and University Hospital Cologne, University of Cologne, Cologne, Germany |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/34013969$$D View this record in MEDLINE/PubMed |
| BookMark | eNpNUEtLw0AYXKRiH_oXyh69pO4radabpD4KhV5UvIXd5Eu7stmN2aSl_96gFTzNwDxgZopGzjtAaE7JghLC7qhIYprG6SJbEcoTQhZNr8UFmgyCjITkH6N_fIymIXwSwiWl6RUaczGEZCInqMq8OygLoQDX4caqUCvsW7w_NdCauu4d4B_wO-t1b43D1SA34BsL-Gi6Pc627-tVROU9Vtiag3E7HE6hg1p1psAtHAwcr9FlpWyAmzPO0NvT42v2Em22z-vsYRMVYslFBKRMqVKsrPQyrhRnjOg4oaSMOWWQgCih4IleKgI6ZVTxQlMaK1pyYEwIxWbo9re3af1XD6HLazNMs1Y58H3IWcykFGJoG6zzs7XXNZR5M8xV7Sn_-4Z9A2PQaso |
| CitedBy_id | crossref_primary_10_7326_M22_1079 crossref_primary_10_7326_M22_2202 crossref_primary_10_7326_M21_3507 crossref_primary_10_1016_j_anpedi_2021_05_019 crossref_primary_10_1136_jim_2021_002158 crossref_primary_10_2174_1570180819666220527160528 crossref_primary_10_3389_fimmu_2023_1055457 crossref_primary_10_1002_14651858_CD013600_pub6 crossref_primary_10_1055_a_2013_8775 crossref_primary_10_3390_ijerph19106147 crossref_primary_10_1136_bmjgh_2022_009378 crossref_primary_10_4274_tybd_galenos_2023_58815 crossref_primary_10_1080_08880018_2022_2035864 crossref_primary_10_1007_s40262_024_01351_w crossref_primary_10_2147_DDDT_S356951 crossref_primary_10_1002_hsr2_1949 crossref_primary_10_1128_jvi_01551_21 crossref_primary_10_3389_fmed_2021_641429 crossref_primary_10_1186_s12916_023_03161_6 crossref_primary_10_3389_fimmu_2022_773652 crossref_primary_10_1111_trf_17151 crossref_primary_10_1111_trf_17174 crossref_primary_10_1111_tid_14144 crossref_primary_10_1186_s13063_022_06929_y crossref_primary_10_1186_s12879_022_07551_8 crossref_primary_10_1007_s12288_021_01457_2 |
| ContentType | Journal Article |
| Copyright | Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |
| Copyright_xml | – notice: Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |
| DBID | CGR CUY CVF ECM EIF NPM 7X8 |
| DOI | 10.1002/14651858.CD013600.pub4 |
| DatabaseName | Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed MEDLINE - Academic |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) MEDLINE - Academic |
| DatabaseTitleList | MEDLINE MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | no_fulltext_linktorsrc |
| Discipline | Medicine |
| EISSN | 1469-493X |
| ExternalDocumentID | 34013969 |
| Genre | Meta-Analysis Research Support, Non-U.S. Gov't Systematic Review Journal Article |
| GroupedDBID | --- 53G 5GY 7PX 9HA ABJNI ACGFO ACGFS AENEX ALMA_UNASSIGNED_HOLDINGS ALUQN AYR CGR CUY CVF D7G ECM EIF HYE NPM OEC OK1 P2P RWY WOW ZYTZH 7X8 |
| ID | FETCH-LOGICAL-c4734-e0d81aa2dfb75fa3220b5610d5312e6e4dec36b7a0eb821a3cb115a1d3e2244a2 |
| IEDL.DBID | 7X8 |
| ISICitedReferencesCount | 26 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000660970700039&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1469-493X |
| IngestDate | Fri Jul 11 10:04:11 EDT 2025 Thu Jan 02 22:53:11 EST 2025 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Language | English |
| License | Copyright © 2021 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd. |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-c4734-e0d81aa2dfb75fa3220b5610d5312e6e4dec36b7a0eb821a3cb115a1d3e2244a2 |
| Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 23 ObjectType-Undefined-3 |
| OpenAccessLink | https://www.cochranelibrary.com/cdsr/doi/10.1002/14651858.CD013600.pub4/pdf/full |
| PMID | 34013969 |
| PQID | 2529944312 |
| PQPubID | 23479 |
| ParticipantIDs | proquest_miscellaneous_2529944312 pubmed_primary_34013969 |
| PublicationCentury | 2000 |
| PublicationDate | 2021-05-20 |
| PublicationDateYYYYMMDD | 2021-05-20 |
| PublicationDate_xml | – month: 05 year: 2021 text: 2021-05-20 day: 20 |
| PublicationDecade | 2020 |
| PublicationPlace | England |
| PublicationPlace_xml | – name: England |
| PublicationTitle | Cochrane database of systematic reviews |
| PublicationTitleAlternate | Cochrane Database Syst Rev |
| PublicationYear | 2021 |
| References | 33044747 - Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600 36734509 - Cochrane Database Syst Rev. 2023 Feb 1;2:CD013600 |
| References_xml | – reference: 36734509 - Cochrane Database Syst Rev. 2023 Feb 1;2:CD013600 – reference: 33044747 - Cochrane Database Syst Rev. 2020 Oct 12;10:CD013600 |
| SSID | ssj0039118 |
| Score | 2.6547606 |
| SecondaryResourceType | review_article |
| Snippet | Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential... Convalescent plasma and hyperimmune immunoglobulin may reduce mortality in patients with viral respiratory diseases, and are being investigated as potential... |
| SourceID | proquest pubmed |
| SourceType | Aggregation Database Index Database |
| StartPage | CD013600 |
| SubjectTerms | Bias Cause of Death COVID-19 - mortality COVID-19 - therapy COVID-19 Serotherapy Humans Immunization, Passive - adverse effects Immunization, Passive - methods Immunization, Passive - mortality Immunization, Passive - statistics & numerical data Non-Randomized Controlled Trials as Topic - statistics & numerical data Pandemics Randomized Controlled Trials as Topic - statistics & numerical data Respiration, Artificial - statistics & numerical data Treatment Outcome Ventilator Weaning - statistics & numerical data |
| Title | Convalescent plasma or hyperimmune immunoglobulin for people with COVID-19: a living systematic review |
| URI | https://www.ncbi.nlm.nih.gov/pubmed/34013969 https://www.proquest.com/docview/2529944312 |
| Volume | 5 |
| WOSCitedRecordID | wos000660970700039&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwpV1LS8NAEF7Uinjx_agvVvC6drOPZONFpLUo2NqDSm5hs9lgwSa1tYL_3tkktSdB8JKcApvNNzNfZma_QejChL4RQliShZwSwYwkWktNlJYQ3SDGiUoy_yHo91UUhYM64Tat2yrnPrF01GlhXI68xSQ4TgHhjl2P34mbGuWqq_UIjWXU4EBlHKqD6KeKwMGQVXW6yE1S49H8hDBlLc_NAFdSXbY7TrWMUvf64neaWYab7uZ_F7qFNmqiiW8qZGyjJZvvoLVeXUrfRVm7yAFllZoTHgOJHmlcTPDrVyn5P5rlFpe3wmmGuH51DPwWVx3n2KVvcfvx5b5DvPAKa_w2dJkJvBCGxtWhmD303L19at-ReugCMSLggliaKk9rlmZJIDMN9k4Tx7FSMFZmfStSa7ifBJraRDFPc5MAqdReyi2wAaHZPlrJi9weIqyDjPEwlcw3SiTUV4kPhEKGiQTYKMma6Hy-gzGA2lUqdG6L2TRe7GETHVSfIR5X6hsxd3-EoR8e_eHpY7TOXA8KleANTlAjA5O2p2jVfH4Mp5OzEi1w7Q963-vcyM0 |
| linkProvider | ProQuest |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Convalescent+plasma+or+hyperimmune+immunoglobulin+for+people+with+COVID-19%3A+a+living+systematic+review&rft.jtitle=Cochrane+database+of+systematic+reviews&rft.au=Piechotta%2C+Vanessa&rft.au=Iannizzi%2C+Claire&rft.au=Chai%2C+Khai+Li&rft.au=Valk%2C+Sarah+J&rft.date=2021-05-20&rft.eissn=1469-493X&rft.volume=5&rft.spage=CD013600&rft_id=info:doi/10.1002%2F14651858.CD013600.pub4&rft_id=info%3Apmid%2F34013969&rft_id=info%3Apmid%2F34013969&rft.externalDocID=34013969 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1469-493X&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1469-493X&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1469-493X&client=summon |